Randomized, double-blind, placebo-controlled phase IIb/III study to evaluate the efficacy and safety of espesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: BOEHRINGER INGELHEIM ESPAÑA, SA
- Phase: III
- Execution start: 13/03/2023
- End of execution: 30/09/2028
- PI: RICARDO RUIZ VILLAVERDE
